Biotech Values : PCVX +66% on VAX-24 phase-1/2 data in ad...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

News Focus

News Focus

Biotech Values

Keep Last Read

Replies (3) Next 10 Prev Next

Send PM Follow Ignore

Followers	843
Posts	123038
Boards Moderated	9
Alias Born	09/05/2002

Re: DewDiligence post# 241577

Monday, 10/24/2022 11:26:21 AM

Monday, October 24, 2022 11:26:21 AM

PCVX +66% on VAX-24 phase-1/2 data in adults, showing comparable efficacy/tolerability to Prevnar-20:

https://www.globenewswire.com/news-release/2022/10/24/2539776/0/en/Vaxcyte-Reports-Positive-Topline-Data-from-Phase-1-2-Proof-of-Concept-Study-of-its-24-Valent-Pneumococcal-Conjugate-Vaccine-Candidate-Being-Investigated-for-the-Prevention-of-Invas.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Keep Last Read

Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow